Abstract
The selective bradykinin analogue, RMP-7, transiently increases the permeability of the blood brain barrier and the delivery of hydrophilic agents into brain tumours. In 87 recurrent glioma patients (WHO Grade III/IV, median age 46, Karnofsky 70%) clinical and Magnetic Resonance Imaging (MRI) responses to i.v. cycles (q 28 days) of RMP-7 (300 ng/kg given as a 10 min infusion) and carboplatin (AUC 4-9) were assessed. 45 of these patients were chemotherapy naive (CN-RMP) and 42 had received one prior course of chemotherapy (CP-RMP). Neurological impairment, performance status and steroid use were measured prior to dosing at each cycle and tumour volume by 3-D MRI at the end of cycles 2, 4, 6, 9 and 12. Clinical evaluation of response demonstrated that 61% of CN-RMP patients were either stable or improved whilst this was 39% for CP-RMP patients, of which 37% and 8% improved respectively. Radiological evaluation showed 79% of CN-RMP patients were either stable, partial or complete responses and 24% for CP-RMP patients, of which 32% and 5% were CR or PR respectively.
The median duration of response was 30.3 weeks in CN-RMP patients and 19.6 weeks in the CP-RMP group. Lack of response was associated with substantial baseline tumour volume. Drug toxicity was as previously reported for carboplatin. 11 patients had treatment-associated transient focal seizures. These results indicate that RMP-7 and carboplatin have significant activity in recurrent malignant glioma following radiotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bleehen NM, Stenning SP on behalf of the Medical Research Council Brain Tumour Working Party: A medical research council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Brit J Cancer 64: 769-774, 1991
Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB: Modified procarbazine, CCNU and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumours. Cancer Treatment Reports 64: 203, 1980
Fine HA: The basis for current treatment recommendations for malignant gliomas. J Neuro-Oncol 20: 111-120, 1994
Canetta R, Goodlow J, Smaldone L, Bragman K, Rozencweig M: Pharmacologic characteristics of carboplatin: clinical experience. In: Bunn PA Jr, Canetta R, Ozols RF, Rozencweig M (eds) Carboplatin (JM-8) Current Perspectives and Future Directions. WB Saunders Company, 1990, pp 19-37
Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520-528, 1992
Doz F, Berens ME, Dougherty DV, Rosenblum ML: Comparison of cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. J Neuro-Oncol 11: 27-35, 1991
Shinohara C, Matsumoto K, Meada Y, Tada E, Kuriyama M, Adachi H, Ono Y, Higashi H, Furata T, Ohmoto T: Synergistic effect of carboplatin and hyperthermia in rat and human glioma cell lines. Neurol Surg 22, 11: 1029-1033, 1994
Dodion P, Sanders C, Georges P, KenisY: In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin. Cancer Chemother Pharmacol 22: 80-82, 1988
Yung WK, Mechtler L, Gleason MJ: Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncols 9(5): 860-864, 1991
Warnick RE, Prados MD, Mack EE, Chandler KL, Doz F, Rabbitt JE, Malek MK: A phase II study of intravenous carboplatin for the treatment of recurrent glioma. J Neuro-Oncol 19(1): 69-74, 1994
Matsukado K, Inamura T, Nakano S, Fukui M, Bartus RT, Black KL: Enhanced tumour uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 39(1): 125-134, 1997
Ford J, Osborn C, Barton T, Bleehen NM: Phase I Study of Intravenous RMP-7 with Carboplatin in Patients with Progression of Malignant Glioma. Eur J Cancer (in press)
Gehan EA: he determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346-353, 1961
WHO publication No 48, WHO publications Centre USA, NY 12210, USA
Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989
Hopper KD, Kasales CJ, Eggli KD, Belman NM, Potok PS, Ten Have TR, Umlauf MJ, Van Slyke MA, Olt GJ, Close P, Lipton A, Harvey HA, Hartell JS, Go BDM: 2D versus 3D quantitation of tumour response to treatment. In: Quantitative Imaging in Oncology. Proceedings of the 19th LH Gray Conference. Faulkner K, Carey B, Crellin A and Harrison RM (eds). Pub British Institute of Radiology, London, 1996
Grant R, Slattery J, Gregor A, Whittle IR: Recording neurological impairment in clinical trials of glioma. J Neuro Oncol 19: 37-49, 1994
Clyde Z, Chataway J, Grant R: The Edinburgh Functional Impairment Tests - detecting change in functional impairments in patients with cerebral glioma. Brit J Neurosurg 10(1): 124-125, 1996 (Abstract)
Grant R, Collie D: The effect of clinical presentation on management and outcome in patients with high grade glioma. J Neuro Onc 21: 20, 1994 (Abstract)
Clyde Z, Grant R: Simple objective tests of limb function and memory are valuable in assessing patients with brain tumors. Neurology A321: PO4.124, 1996 (Abstract)
Chataway SJS, Clyde Z, Signorini DF, Whittle IR, Grant R: What represents a clinically significant change in outcome measures following operation for brain tumour? J Neuro-Oncol, 1997 (submitted)
Yates JW, Chalmer B, McKegney FP: Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45: 2220-2224, 1980
Macdonald DR, Cascino TL, Schold SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7): 1277-1280, 1990
Alvord EC: Patterns of growth of gliomas. American J Neuro Radiology 16: 1013-1017, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gregor, A., Lind, M., Newman, H. et al. Phase II Studies of RMP-7 and Carboplatin in the Treatment of Recurrent High Grade Glioma. J Neurooncol 44, 137–145 (1999). https://doi.org/10.1023/A:1006379332212
Issue Date:
DOI: https://doi.org/10.1023/A:1006379332212